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Carlos O. Mendivil, MD, DSc; Eric B. Rimm, DSc; Jeremy Furtado, DSc; Frank M. Sacks, MD
Background-—Low-density lipoprotein (LDL) with apolipoprotein C-III (apoC-III) is the lipoprotein species that most strongly
predicts initial and recurring coronary heart disease (CHD) events in several cohorts. Thus, a large portion of the CHD risk
conferred by LDL may be attributable to LDL that contains apoC-III. Very-low-density lipoprotein (VLDL) and LDL with apoC-III have
varying amounts of apoE. We hypothesized that a high content of apoE lessens the adverse inﬂuence of apoC-III on the risk of CHD
because it promotes the clearance of VLDL and LDL from plasma.
Methods and Results-—We studied 2 independent cohorts, the Nurses’ Health Study, composed of women, and the Health
Professionals Follow-up Study, composed of men. These cohorts contributed to this study 322 women and 418 men initially free of
CVD who developed a fatal or nonfatal myocardial infarction during 10 to 14 years of follow-up and matched controls who
remained free of CHD. The apoE content of LDL with apoC-III was inversely associated with CHD after multivariable adjustment
(relative risk for top versus bottom quintile 0.53, 95% CI 0.35 to 0.80). The apoE content of VLDL with apoC-III had a similar inverse
association with CHD. The highest risks were associated with a high apoB concentration and a low apoE content of LDL with
apoC-III or of VLDL+LDL with apoC-III. The observed associations were in both male and female cohorts and independent of
traditional CHD risk factors and of C-reactive protein.
Conclusions-—An increased apoE content in VLDL and LDL with apoC-III was associated with a lower risk of CHD. Strategies to
enrich VLDL and LDL in apoE are worth exploring for the prevention of CHD. (J Am Heart Assoc. 2013;2:e000130 doi: 10.1161/
JAHA.113.000130)
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A
polipoprotein E (apoE) is a small apolipoprotein synthe-
sized mostly by the liver that serves as a ligand to the
low-density lipoprotein (LDL) receptor (LDLR) and the LDL-
receptor–related protein-1 (LRP1) and plays an essential role
in metabolism by promoting cellular uptake of lipoproteins.
1,2
Even though most plasma apoE is borne in HDL and VLDL,
there is a measurable concentration of apoE in LDL that is
distributed throughout its conventional density range that
includes the intermediate-density lipoproteins (IDL) and light
and dense LDL.
3,4 The usual plasma concentration of apoE
ranges between 6 and 10 mg/dL,
5 of which 25% to 50% is
associated with VLDL, 10% to 25% with IDL/LDL, and 30% to
50% with HDL. apoE has a very high afﬁnity for the LDL
receptor, actually much superior to that of apoB-100
6; hence,
apoE in VLDL and LDL may inﬂuence the plasma concentra-
tion and metabolic destination of these lipoproteins, with
potential implications for atherogenesis and the occurrence of
cardiovascular disease (CVD). In addition, apoE has diverse
proposed antiatherogenic properties independent of its role
on lipoprotein uptake.
7
Even though genetic variations at the APOE gene have been
extensively studied as predictors of cardiovascular events,
8–10
very few studies have analyzed concentrations of the apoE
protein as predictors of cardiovascular outcomes or how they
are affected by concentrations of apolipoprotein C-III (apoC-
III). One study in adults older than 85 years
11 found a positive
association between total plasma apoE concentrations and
cardiovascular mortality, and another reported a generally
increased risk of stroke with higher plasma apoE in the same
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12 However, plasma total apoE is
distributed among all lipoprotein classes, and a considerable
amount of apoE is in HDL. The apoE content of HDL is
associated with recurrent coronary heart disease (CHD)
events.
13 Thus, the inﬂuence of apoE on atherosclerosis and
CHD may depend on the lipoprotein where it is located.
ApoC-III is another small apolipoprotein with metabolic
actions antagonistic to those of apoE; apoC-III impedes binding
of VLDL to cellular receptors, channeling the metabolism of
VLDL away from clearance from the circulation and toward
conversion to LDL, especially dense LDL.
14,15 apoC-III also
speciﬁcally and directly induces proatherogenic changes in
monocytes and endothelial cells.
16 The plasma concentration
of apoC-III in VLDL and LDL is associated with CHD in
retrospective studies
17,18 and predicts initial and recurrent
CHD in prospective studies.
13 Among the concentrations of
the apoB lipoproteins, the plasma concentration of LDL with
apoC-III predicts most strongly the incidence of recurrent
cardiovascular events in type 2 diabetes
19 and ﬁrst coronary
event in 2 US cohorts initially free of CHD.
20 The relative risk of
a recurrent event in the cohort with type 2 diabetes was 6.2 for
the ﬁfthversus ﬁrst quintile of LDL with apoC-III compared with
2.2 for the ﬁfth versus ﬁrst quintile of LDL without apoC-III. In
the 2 US cohorts of men and women, the relative risk of a ﬁrst
coronary event was 2.4 for LDL with apoC-III compared with
1.2 for LDL without apoC-III,
20 and the test for interaction was
signiﬁcant demonstrating that the prediction of CHD risk by
the 2 types of LDL differed signiﬁcantly. Interestingly, about
30% of LDL that has apoC-III also has apoE.
3,4 It could be that
the balance between the apoE and apoC-III contents of an
individual’s LDL affects the physiology of LDL and, subse-
quently, the progression of atherosclerosis and the occurrence
of a coronary event. On the other hand, since nearly all of the
apoE in LDL is in LDL with apoC-III
3,4 (Figure 1), it follows that
the inﬂuence of apoE needs to be studied in the context of
apoC-III–containing LDL, and in this study we have focused our
study on apoE in LDL that also contains apoC-III.
We explored whether the apoE content of LDL and VLDL
with apoC-III (expressed as the molar ratio of apoE to apoB in
these particles) may be associated with an attenuated CHD
risk. We prospectively studied this relationship in 2 large US
cohorts of women and men, the Nurses’ Health Study (NHS)
and the Health Professionals Follow-up Study (HPFS), sepa-
rately and combined.
Methods
Study Population
The NHS and the HPFS are prospective cohort investigations
respectively involving 121 700 female US registered nurses
who were 30 to 55 years old at baseline in 1976 and 51 529
US male health professionals who were 40 to 75 years old at
baseline in 1986. Information about health and disease is
assessed biennially.
21–24
From 1989 through 1990, a blood sample was requested
from all participants in the NHS, and 32 826 women provided
one. Similarly, between 1993 and 1995, a blood sample was
provided by 18 225 men in the HPFS. Participants who
provided blood samples were similar to those who did not. In
the NHS, among women without CVD or cancer before 1990,
we identiﬁed 350 women who had a nonfatal myocardial
infarction or fatal CHD between the date of blood drawing and
June 2004. In the HPFS, we identiﬁed 425 men initially free of
CVD who had a nonfatal myocardial infarction or fatal CHD
between the date of blood draw and the return of the 2004
questionnaire. Using risk-set sampling,
25 we randomly
selected controls in a 1:1 ratio who were matched for age
(1 year), smoking status (never, past, or current), and date
of blood sampling (2 months) from the participants who
were free of CVD at the time CHD was diagnosed in the case
patients. Within the NHS cohort, an additional matching
criterion was fasting status at the time of blood sampling.
Assessment of CHD
Study physicians who were unaware of the participant’s
exposure status conﬁrmed the diagnosis of myocardial
infarction on the basis of the criteria of the World Health
Organization. Deaths were identiﬁed from state vital records
and the National Death Index or reported by the participant’s
next of kin or the postal system. Fatal CHD was conﬁrmed by
an examination of hospital or autopsy records, by the listing of
CHD as the cause of death on the death certiﬁcate, if CHD
was the underlying and most plausible cause, and if evidence
of previous CHD was available.
Assessment of Other Factors
Medical history, lifestyle, and demographic information was
derived from the questionnaire administered in 1990 to
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Figure 1. Relative distribution of the plasma LDL subpopulations
according to contents of apoE and apoC-III.
3,4 Data expressed as
percentageoftotalLDLapoBconcentration.LDLindicateslow-density
lipoprotein; apoE, apolipoprotein E; apoC-III, apolipoprotein C-III.
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Hwomen and 1994 to men, with missing information substi-
tuted from previous questionnaires. Physical activity was
expressed in terms of metabolic equivalent (MET)-hours. The
questionnaires and the validity and reproducibility of mea-
surements have been described previously.
21–24
Measurement of Lipid and Apolipoprotein Levels
Blood samples from women were collected in heparin-treated
tubes and samples from men in EDTA-treated tubes. The
tubes were placed on ice packs, shipped in Styrofoam
containers by overnight courier, centrifuged, divided into
aliquots, and stored in liquid-nitrogen freezers (130°Co r
colder). One vial containing 0.6 mL (NHS) or 0.5 mL (HPFS) of
frozen plasma was shipped to the lipoprotein laboratory at the
Harvard School of Public Health for analysis of lipoprotein
types. Study samples were sent to the laboratory for analysis
in randomly ordered batches, and the laboratory personnel
were unaware of a sample’s case–control status. The entire
plasma sample was thawed, ﬁltered, and incubated overnight
with afﬁnity-puriﬁed anti–apoC-III antibodies (Academy Bio-
medical) bound to Sepharose 4B resin, as previously
described and validated.
3,26 The unbound lipoproteins that
did not contain apoC-III were collected by gravity ﬂow, and the
bound lipoproteins that contained apoC-III were eluted with
3 mol/L sodium thiocyanate. The efﬁciency of the apoC-III
immunoafﬁnity separation (percentage of ligand removed from
plasmabytheresin)was99%.VLDL(densitybelow1.006 g/mL)
and LDL (density between 1.006 and 1.063 g/mL) were
isolated from plasma with and without apoC-III by ultracen-
trifugation.
27 We used the 1.006 g/mL lower cutoff for LDL to
include IDL in our analysis. A small amount of large-size
lipoprotein (a) [Lp(a)] could have been included in this density
range. We note here that apoB-containing remnants of
metabolism of triglyceride-rich VLDL are contained through-
out the density interval 1.006 to 1.063 as directly determined
by tracer kinetic studies.
4 ApoB, apoE, and apoC-III were
measured in the lipoprotein fractions by enzyme-linked
immunosorbent assay, and cholesterol and triglycerides were
measured by enzymatic methods (Inﬁnity Kit; Thermo Fischer
Scientiﬁc).
As mentioned in the introduction, we did not measure apoE
in LDL without apoC-III because in previous studies
3,4 we have
found the concentration of this lipoprotein type (LDL with
apoE and without apoC-III) to be negligible or undetectable in
most individuals.
The study protocol was approved by the institutional
review board of the Brigham and Women’s Hospital and the
Human Subjects Committee Review Board of the Harvard
School of Public Health. After excluding participants with
missing data for apoB in one or more of the LDL and VLDL
fractions, the dataset consisted of 1476 participants (322
female and 418 male cases and 322 female and 418 male
controls). The cases were identiﬁed and the controls selected
in 2-year cycles. Two men and 2 women selected as controls
in one cycle later developed CHD and were selected in a
subsequent cycle, this time as cases. For this reason, the
study sample contains 1476 and not 1480 individuals. For
these 4 participants, we used the same baseline measure-
ments in the pair where they were cases and in the pair where
they were controls. Our main exposure was the content of
apoE in LDL with apoC-III, measured as the number of apoE
molecules per LDL particle (apoE:apoB molar ratio).
Statistical Analysis
Apolipoprotein measurements were divided into quintiles,
from the lowest to highest levels, on the basis of the sex-
speciﬁc distributions among the controls. We analyzed the
association between apolipoprotein levels and the risk of CHD
using conditional logistic regression. With risk-set sampling,
the odds ratio derived from the logistic regression directly
estimates the hazard ratio and, thus, the relative risk.
25 We
analyzed our main exposure in 3 logistic models: model 1
conditioned on matching factors only; model 2 with additional
adjustment for parental history of CHD before the age of
60 years, alcohol intake, and history of hypertension at
baseline; and model 3 with adjustment for all the variables in
model 2 plus body mass index and history of diabetes at
baseline. In additional models, we also adjusted for the
plasma LDL cholesterol concentration and by plasma con-
centrations of C-reactive protein (CRP). Baseline was deﬁned
as the year in which blood was drawn. To test for linear trend,
we used the median levels of apolipoprotein measurements in
the control quintile categories as a continuous variable. We
analyzed all quintiles for all variables, but for ease of reading
in Table 2 we display only the relative risk for quintile 5
compared with quintile 1 and the P value for trend across
quintiles. All P values are 2-tailed, and P values <0.05 were
considered to indicate statistical signiﬁcance. All analyses
were performed with the use of SAS software, version 9.1
(SAS Institute).
Results
The average content of apoE (as reﬂected by the apoE:apoB
molar ratio) in LDL with apoC-III was signiﬁcantly lower in
cases than in matched controls of both sexes (Table 1).
Meanwhile, the apoE content of VLDL with apoC-III was not
different in cases and controls.
In these cohorts, we have found the association of LDL
with apoC-III with CHD to be markedly and signiﬁcantly
greater than that of LDL without apoC-III.
20 In the present
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each LDL with apoC-III (apoE content per particle) predicted a
markedly lower risk of CHD (relative risk for top versus
bottom quintile 0.45, 95% CI 0.31 to 0.64), which continued
to be signiﬁcant after multivariable adjustment (Table 2 and
Figure 2).
The apoE content of VLDL with apoC-III, expressed as the
apoE:apoB molar ratio in this fraction, also showed a strong
negative association with CHD (relative risk for top versus
bottom quintile 0.50, 95% CI 0.35 to 0.72; P for trend <0.001)
that persisted after additional multivariable adjustment in
models 2 and 3 (Table 2 and Figure 2). The results in terms of
Table 1. Baseline Characteristics of the Study Sample
Characteristic
Women* Men*
Cases
(n=322)
Controls
(n=322) P Value
†
Cases
(n=418)
Controls
(n=418) P Value
†
Age, y 6066 0 6 — 64.58 64.58 —
Current smoker, % 26 26 — 98—
Body mass index, kg/m
2 26.75.6 25.44.3 0.001 26.13.2 25.53.5 0.014
Parental history of CHD before age 60 y, % 20 15 0.073 15 12 0.26
Postmenopausal, % 91 88 0.30 ———
Postmenopausal hormone therapy
among postmenopausal women, %
33 35 0.55 ———
Aspirin use, %
‡ 26 30 0.28 40 33 0.035
History of hypertension, % 54 32 <0.001 37 28 0.005
History of diabetes, % 17 7 <0.001 9 3 <0.001
Alcohol consumption, g/d
Median 0.9 1.1 0.17 4.5 7.5 0.006
Quartile 1 to quartile 3 0 to 4.7 0 to 6.4 — 0 to 15 1.0 to 18.3 —
Total cholesterol, mmol/L 6.11.2 61.2 0.20 5.61 5.40.9 0.002
LDL cholesterol, mmol/L 3.81 3.71 0.077 3.50.9 3.30.8 <0.001
HDL cholesterol, mmol/L 1.30.4 1.50.4 <0.001 1.10.3 1.20.3 <0.001
Total:HDL cholesterol ratio 3.71.5 3.41.6 0.08 3.71.1 3.41.4 0.002
Triglycerides (mmol/L) 1.61.1 1.30.7 <0.001 1.50.9 1.30.8 <0.001
C-reactive protein, mg/L
Median 0.51 0.38 0.34 0.34 0.26 0.86
Quartile 1 to quartile 3 (interquartile range) 0.20 to 1.50 0.14 to 0.96 — 0.13 to 1.01 0.09 to 0.86 —
Total plasma apoB, g/L 0.920.28 0.880.31 0.14 0.970.28 0.900.26 <0.001
apoE in VLDL with apoCIII, g/L 0.00460.0039 0.00400.0032 0.075 0.0130.009 0.0120.008 0.08
apoE in LDL with apoCIII, g/L 0.00910.008 0.00890.0065 0.80 0.00930.0064 0.00890.0062 0.30
apoE in HDL, g/L 0.0094 0.0086 0.58 0.0069 0.0067 0.48
apoE:apoB molar ratio in VLDL with apoC-III 7.87.0 9.09.1 0.093 10.67.0 11.17.9 0.32
apoE:apoB molar ratio in LDL with apoC-III 2.01.3 2.41.6 0.001 1.30.9 1.50.9 0.044
apoE:apoCIII molar ratio in VLDL 0.090.14 0.090.11 0.99 0.150.12 0.160.13 0.83
apoE:apoCIII molar ratio in LDL 0.120.17 0.130.16 0.42 0.100.08 0.130.52 0.24
Matching criteria were age, smoking status, and date of blood sampling; among women, additional matching criteria included fasting status at the time of blood sampling. The values are
meanSD. The body mass index is the weight in kilograms divided by the square of the height in meters. CHD indicates coronary heart disease; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; VLDL, very low-density lipoprotein; apoE, apolipoprotein E; apoB, apolipoprotein B; apoC-III, apolipoprotein C-III.
*Data on women are from the Nurses’ Health Study and include 14 years of follow-up, and data on men are from the Health Professionals Follow-up Study and include 10 years of follow-
up.
†P values for the difference between patients and controls (unadjusted) were determined by Student t test for variables expressed as meanSD values, by Wilcoxon’s rank-sum test for
variables expressed as median values, and by the v
2 test for variables expressed as percentages.
‡Current aspirin use was deﬁned as every 1 to 4 days per week for women and as 2 or more times per week for men.
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NHS cohorts were analyzed separately (Figure S1).
To explore the inﬂuence of apoE on all atherogenic (ie, non-
HDL) lipoproteins simultaneously, we analyzed the relative
risks of CHD by quintiles of apoE content in VLDL+LDL. A
higher content of apoE in VLDL+LDL with apoC-III was
associated with a markedly lower risk of CHD (relative risk for
top versus bottom quintile 0.43, 95% CI 0.30 to 0.62; P for
trend <0.001), and apoE in VLDL+LDL with apoC-III continued
to show a protective association after adjustment for major
cardiovascular risk factors, body mass index, and personal
history of diabetes (relative risk 0.53, 95% CI 0.35 to 0.79;
P for trend 0.002) (Table 2 and Figure 2).
Given that plasma concentrations of both VLDL and LDL
with apoC-III have been found to predict cardiovascular
events,
20 we explored whether the association between the
concentration of this type of lipoproteins (expressed as the
apoB concentration in these fractions) and CHD would be
modulated by their content of apoE. The highest risk was
associated with a high concentration of VLDL+LDL apoC-III
and a low content of apoE in this lipoprotein type or with a
high concentration of LDL apoC-III and a low content of apoE
(Figure 3). A higher apoE content was associated with lower
risk across the second and third tertiles of VLDL + LDL with
apoC-III and of LDL with apoC-III (Figure 3), with no signiﬁcant
interaction (P value for interaction=0.36), suggesting that a
high content of apoE has the potential to attenuate risk
conferred by VLDL and LDL with apoC-III or LDL with apoC-III,
even when their plasma concentration is high.
Adjustment for plasma LDL cholesterol in the background
of multivariable model 3 only slightly attenuated the negative
association between apoE content of LDL that has apoC-III
and CHD (relative risk 0.62, 95% CI 0.41 to 0.93) and between
apoE content of VLDL that has apoC-III and CHD (relative risk
0.61, 95% CI 0.40 to 0.93). The same pattern was observed in
multivariable models adjusted for plasma HDL cholesterol or
plasma triglycerides. The associations for both apoE content
of LDL with apoC-III and apoE content in VLDL with apoC-III
were only slightly attenuated. Given that apoE has been
proposed to have anti-inﬂammatory properties,
7 we
Table 2. Relative risks of CHD by quintiles of apoE content in
LDL, VLDL, or VLDL+LDL with apoC-III
Relative Risk for
Q5 vs Q1
P Value
for Trend
apoE:apoB molar ratio in VLDL with apoC-III
Model 1 0.50 (0.35 to 0.72) <0.001
Model 2 0.48 (0.32 to 0.72) 0.002
Model 3 0.52 (0.34 to 0.79) 0.005
Model 3+plasma LDL cholesterol 0.61 (0.40 to 0.94) 0.040
Model 3+plasma HDL cholesterol 0.61 (0.40 to 0.94) 0.048
Model 3+plasma triglycerides 0.60 (0.39 to 0.92) 0.030
Model 3+plasma
C-reactive protein
0.51 (0.34 to 0.78) 0.005
apoE:apoB molar ratio in LDL with apoC-III
Model 1 0.45 (0.31 to 0.64) <0.001
Model 2 0.47 (0.32 to 0.70) <0.001
Model 3 0.53 (0.35 to 0.80) 0.002
Model 3+plasma LDL cholesterol 0.64 (0.42 to 0.97) 0.041
Model 3+plasma HDL cholesterol 0.65 (0.43 to 1.00) 0.038
Model 3+plasma triglycerides 0.69 (0.44 to 1.08) 0.09
Model 3+plasma
C-reactive protein
0.53 (0.35 to 0.80) 0.002
apoE:apoB molar ratio in VLDL+LDL with apoC-III
Model 1 0.43 (0.30 to 0.62) <0.001
Model 2 0.48 (0.32 to 0.71) <0.001
Model 3 0.53 (0.35 to 0.79) 0.002
Model 3+plasma LDL cholesterol 0.63 (0.41 to 0.96) 0.05
Model 3+plasma HDL cholesterol 0.60 (0.40 to 0.90) 0.018
Model 3+plasma triglycerides 0.63 (0.41 to 0.95) 0.034
Model 3+plasma
C-reactive protein
0.50 (0.33 to 0.75) 0.001
Model 1 is conditioned on matching factors only; model 2 is additionally adjusted for
parental history of CHD before the age of 60 years, alcohol intake, and history of
hypertension at baseline. Model 3 is adjusted for everything in model 2 plus body mass
index and history of diabetes at baseline. Relative risks and 95% CIs are given for the
highest quintile compared with the lowest quintile of each variable. CHD indicates
coronary heart disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL,
very-low-density lipoprotein; apoE, apolipoprotein E; apoB, apolipoprotein B; apoC-III,
apolipoprotein C-III; Q, quintile.
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Figure 2. RelativerisksofCHDaccording toapoEcontents ofVLDL,
LDL, or VLDL+LDL (separate models for each fraction). Median apoE
contentsforeachquintileareshowninFigureS1.Allrisksshowninthis
ﬁgure are derived from model 3 (Table 2), conditioned on matching
factors and adjusted for parental history of CHD before the age of
60 years, alcohol intake, history of hypertension at baseline, body
mass index, and history of diabetes at baseline. Points represent
relative risks; error bars represent 95% CIs. CHD indicates coronary
heart disease; VLDL, very low-density lipoprotein; LDL, low-density
lipoprotein; apoE, apolipoprotein E; apoC-III, apolipoprotein C-III.
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plasma CRP levels. In these models, the apoE content of
LDL with apoC-III (relative risk 0.52, 95% CI 0.34 to 0.78) and
the apoE content of VLDL with apoC-III (relative risk 0.51, 95%
CI 0.33 to 0.77), were still inversely associated with CHD
(Table 2).
Finally, to explore the impact of LDL apoE content in a
scenario of constant LDL concentration, we ran a logistic
model that included concentrations of apoB, apoC-III, and
apoE in LDL with apoC-III. In this model, the apoE content of
LDL was still negatively associated with CHD risk (relative risk
0.69, 95% CI 0.45 to 1.07).
Discussion
The results from this prospective study strongly suggest that
the presence of apoE is associated with a lower atherogenic-
ity of LDL that contains apoC-III and that the abundance of
apoE relative to the abundance of LDL with apoC-III is a
protective factor against CHD. The apoE content of VLDL also
exhibited a negative association with CHD. The protective
effect of apoE in LDL appeared to be independent of plasma
LDL cholesterol levels and to persist even when apoC-III levels
in LDL are high.
Even though this ﬁnding makes sense given the biological
antagonism between the 2 apolipoproteins and the well-
documented antiatherogenic properties of apoE,
7 the inﬂu-
ence of apoE in lipoproteins on hard cardiovascular end points
is very scantly documented. Our results also emphasize the
increasingly recognized importance of the composition and
physicochemical properties of lipoproteins as more reﬁned
and often more relevant variables in the exploration of
pathophysiological mechanisms than the total concentrations
of plasma lipids. Even though only 1.5% to 16% of LDL contain
apoC-III,
3 the idea that apoE can effectively protect against
the risk provided by these particles is very appealing if one
considers that LDL with apoC-III are very strongly associated
with CHD
19 and that in fact much of the CHD risk ordinarily
attributed to total LDL may be due to this subpopulation that
contains apoC-III.
20
Prior studies in older adults have found a positive associ-
ation between total plasma apoE levels and CVD mortality
11 or
the risk of stroke.
12 From our results, it is apparent that the
distribution of total plasma apoE across the different lipopro-
tein fractions can greatly affect its association with CVD. In
this respect, an observational analysis of patients from the
Cholesterol and Recurrent Events (CARE) trial found a positive
association between apoE in HDL and the risk of coronary
events.
13 This might explain the positive association between
plasma apoE and CVD in some studies, given that about 40% to
50% of apoE is found on HDL.
5 Nevertheless, our results
suggest that the relatively minor fraction of plasma apoE that
is found in LDL may have a remarkable impact on the risk of
CHD. One study in 2 European countries found higher plasma
apoE concentrations in VLDL+LDL of myocardial infarction
survivors relative to controls who did not survive a coronary
event.
28 In our study, when we exclude the variation in apoB
levels by normalizing apoE to the apoB content per particle,
apoE was clearly protective in both VLDL and LDL. Also,
adjustment for CRP did not diminish the observed effect of
apoE, suggesting that the anti-inﬂammatory properties of apoE
in LDL do not have a major repercussion on its apparent
protective ability against CHD.
Finally, a limitation of our study is that we did not evaluate
the inﬂuence of the apoE e2/e3/e4 polymorphism on the
assessed risks, and apoE isoforms have structural differences
that may modulate their function in LDL.
29 Although genetic
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Figure 3. Relative risks of CHD by joint tertiles of apoE content (apoE:apoB molar ratio) and apoB concentration of VLDL+LDL with apoC-III (left)
or LDL with apoC-III (right). Bars represent relative risks for each joint tertile compared with the reference category (low VLDL+LDL apoC-III
concentration—high apoE/B; or low LDL apoC-III concentration—high apoE/B). CHD indicates coronary heart disease; VLDL, very low-density
lipoprotein; LDL, low-density lipoprotein; apoE, apolipoprotein E; apoC-III, apolipoprotein C-III; Low E, lowest tertile of apoE content; Med E,
medium tertile of apoE content; High E, highest tertile of apoE content.
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apoE concentrations,
30 future studies in which the e2/e3/e4
polymorphism is available will help reﬁne our ﬁndings. In any
event, the evidence we are presenting of an overall protective
role for apoE in VLDL and LDL with apoC-III is a valuable start
point for more detailed study.
In summary, apoE in LDL with apoC-III may mitigate its
atherogenicity and association with CHD. This ﬁnding should
motivate further research on mechanisms to enrich LDL in
apoE as a potential intervention for the prevention of CHD.
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